{
    "nctId": "NCT02386709",
    "briefTitle": "Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer",
    "officialTitle": "Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Treatment in Patients With Mammary Gland Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "FDG PET",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 275,
    "primaryOutcomeMeasure": "difference of \u0394 SUV (Standardised Uptak Value) between 18F-FDG PET 1 and 18F-FDG PET2 to predict pCR during neoadjuvant chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* patient having been informed of the study\n* patient affiliated to a social health insurance\n* \u2265 18 years\n* patient presenting a breast cancer histologically confirmed\n* indication of neoadjuvant chemotherapy treatment (classification UICC: II or III)\n* patient agrees with exploitation of his clinical, biological and image data\n\nExclusion Criteria:\n\n* distant metastasis\n* contraindications to chemotherapy\n* contraindications to surgery\n* refusal\n* serious illness not balanced, subjacent infection\n* pregnancy or breast feeding\n* diabetes not controlled (glycemia\\> 8 mmol/L)\n* psychiatric disease\n* patient under supervision, trusteeship or safeguard of justice",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}